Navigation Links
Promising New Therapy for Drug-Resistant Hypertension Presented at Interventional Cardiology Meeting in Washington, D.C.
Date:9/23/2010

SAN LEANDRO, Calif., Sept. 23 /PRNewswire/ -- Preclinical data of a novel therapy designed to treat drug-resistant hypertension (high blood pressure) was presented Tuesday, September 21st, at the Transcatheter Cardiovascular Therapeutics (TCT) 2010 Conference in Washington, DC, by Christopher D. Owens, MD, MSc, Assistant Professor in Residence, Division of Vascular and Endovascular Surgery, University of California, San Francisco. The therapy pioneered by Mercator MedSystems, Inc., combines the use of the company's Bullfrog® Micro-Infusion Catheter with a known drug to reduce the hyperactivity of nerves in the renal artery leading to and from the kidney. These nerves are implicated in the initiation and maintenance of high blood pressure. The early data shows that this therapy precisely targets these nerves, achieving the desired effect without negatively affecting surrounding tissue. Dr. Owens observed, "While these data are early, the site-specific delivery of drugs directly to the nerves in question offers great promise for a new approach in treating the nearly one-third of 73 million U.S. hypertensive patients who cannot control their blood pressure with medication alone."

The company believes the procedure will take less than an hour in an outpatient setting. In it, the slender Micro-Infusion Catheter is introduced into an artery through a small needle in the upper leg, and is guided into the main kidney artery (the renal artery). Once positioned, a balloon at the tip of the catheter is inflated inside the artery, sliding a 130 micron (two hair widths thick) microneedle through the artery wall into the tissue known as the adventitia, which envelops the hyperactive nerves leading to the kidney. As the drug is infused through the microneedle, it surrounds the artery to create an effective cylindrical treatment zone and reduces the nerve signals which cause high blood pressure.

The company plans to initiate human investigational trials of th
'/>"/>

SOURCE Mercator MedSystems, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Promising Cystic Fibrosis Compound on Track for Development
2. Kiadis Pharma Announces Promising Phase II Clinical Trial Results for Reviroc
3. NicOx Reports TOPIGEN to Advance TPI-1020 Into Phase 2 for COPD Following Promising Clinical Results
4. Promising Data from Paratek Pharmaceuticals MAR Inhibitor Program Presented in Late Breaker Session at the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy
5. The Leukemia & Lymphoma Society is Encouraged by Promising News for Myeloma Patients
6. Promising Results in Treating Facial Bruising From Injectables
7. NicOx and Ferrer Present Promising Clinical and Preclinical Results in Dermatology
8. Promising Phase 3 Trial Results Show Novel Biologic Therapy Ustekinumab (CNTO 1275) Significantly Improved Psoriasis
9. Cutanea Announces Promising Phase II Results in Rosacea with Omiganan
10. AmpliMed Corporation Announces Promising 1-year Survival Data from Phase I/II Study of Amplimexon(R) in Metastatic Malignant Melanoma
11. Protalix BioTherapeutics Extends Research Agreement With Yissum Based on Promising Acetylcholinesterase Program Results in Animal Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/23/2014)... This test can detect HIV infection if used ... by activities that can transfer body fluids from one person ... shared needles. , An in-vitro diagnostic home-use test ... test works by looking for your body,s response to fighting ... enabling patients to learn their status in a single visit ...
(Date:9/23/2014)... Research and Markets has announced the addition ... report to their offering. Though biotechnology ... products to treat cancer, diabetes, HIV/AIDS and autoimmune disorders ... stages of clinical drug testing for new biopharmaceuticals, as ... to upscale while anticipating FDA or EMA approval. During ...
(Date:9/23/2014)... FRANCISCO , Sept. 23, 2014  SiteOne Therapeutics ... of equity financing. Led by Sears Capital Management and ... Joe Zakrzewski , the $1.5 million financing positions ... program for pain and to further develop its technology ... pain indications. In conjunction with the financing, ...
Breaking Medicine Technology:WholeHealth Products announces the release of the FDA Cleared "HIV 1&2" Rapid Diagnostic Test for Professional and Retail 2Biopharmaceutical and Vaccine Production Markets 2Biopharmaceutical and Vaccine Production Markets 3SiteOne Therapeutics Completes $1.5M Initial Round of Equity Financing, Secures $1.4M NIH Grant 2SiteOne Therapeutics Completes $1.5M Initial Round of Equity Financing, Secures $1.4M NIH Grant 3
... HeartSine Technologies, Inc. was honored with the ... 50 event in Stormont, Belfast. The award was presented to ... pioneering business in developing areas of Belfast, Ireland. ... the Long Gallery in Stormont on behalf of HeartSine, said, ...
... N.Y., Oct. 11 Dr. Joan Fallon, founder and CEO ... research and development company focused on the treatment of neurological ... Life Sciences Summit 2010, held September 22-23 in Hauppauge, New ... New York at Stony Brook, Brookhaven National Laboratories and Cold ...
Cached Medicine Technology:HeartSine Technologies Honored With Belfast Ambassador Award at Belfast Business Top 50 Event 2Curemark Moderates Autism Panel at Life Sciences Summit 2010 2Curemark Moderates Autism Panel at Life Sciences Summit 2010 3
(Date:9/23/2014)... Savannah, GA (PRWEB) September 23, 2014 ... local community through philanthropic support. Most recently, the gym ... through their Ageless Fitness program. Throughout the year, World ... for many other charitable causes. , Over the summer, ... Meals on Wheels. Through their Ageless Fitness program, participants ...
(Date:9/23/2014)... Kathleen Doheny HealthDay Reporter ... at very low birth weights, breast milk is more likely ... infection known as cytomegalovirus (CMV), a new study finds. ... infants -- all of whom weighed 3.3 pounds or less ... of CMV infection, to see whether breast milk or transfusions ...
(Date:9/23/2014)... Avid collector Andrew Hawley, from Vintage Rock Posters, ... Seattle concert posters. The Doors were a smash hit after ... The Seattle Eagles Auditorium concert was held on July 23. ... Eagles Auditorium in November the same year. The artist that ... in three colors. The poster is a split fountain silkscreen ...
(Date:9/23/2014)... 2014 (HealthDay News) -- The number of ,rogue, ... is growing, so doctors need to be vigilant ... Administration warned Tuesday. In a statement, the ... it has launched a program to educate doctors ... proper drug purchasing procedures. The program aims to ...
(Date:9/23/2014)... Vancouver, BC (PRWEB) September 23, 2014 ... it will now be offering commercial electrical services in ... scales of operations; whether it is a small maintenance ... will personalize its solution package to meet the needs ... announced that the services will be of an affordable ...
Breaking Medicine News(10 mins):Health News:World of Home Fitness Supports Meals on Wheels 2Health News:Breast Milk a Risk for Spreading Common Virus to Preemies, Study Finds 2Health News:Breast Milk a Risk for Spreading Common Virus to Preemies, Study Finds 3Health News:Pro Ace Now Offers Commercial Electrical Services in Vancouver 2
... According to researchers at Purdue University and the Centers for ... the spread of bird flu in human beings. ,Purdue ... immunity against avian influenza viruses, or bird flu, the most ... in humans. The researchers are focusing on using a harmless ...
... and Colleagues has reported the dosage difference which is ... risk of thyroid cancer. ,The study was ... thyroid cancer during their childhood. The thyroid gland which ... thyroid cancer and there seems to be a relationship ...
... had shown that for obese employees, employers incur an ... with such employees. ,The findings, which appear in ... of Health Promotion, show that for men employed full ... capita cost of being obese, including medical expenses and ...
... everywhere. Atherosclerosis is a big problem and health hazard ... yet another study. ,The study states that supplementation ... // (plaque build-up on the blood vessel walls)., ... homocysteine in the blood. The current study was intended ...
... Researchers from National Cancer Institute has tested the efficacy ... and Anti-androgen hormone therapy to Prostate cancer patients ... no metastatic disease. The Phase II trial was conducted ... but having high Prostate Specific Antigen (PSA) values. The ...
... to handle. Even when so much has been done to ... always been a problem. Viral infections are difficult to ... has always been potent enough to escape even the newer ... as it is called has been posing a challenge for ...
Cached Medicine News:Health News:Risk of Thyroid cancer is increased after Childhood Irradiation of Neck region 2Health News:Combination Therapy To Avoid Prostate Cancer Recurrence 2
... ALLEGRO Topolyzer and T-CAT have been optimized ... vision correction and to interact in perfect ... systems. All necessary treatment and patient parameters ... the ALLEGRETTO WAVE laser systems via diskette, ...
RESTASIS® (cyclosporine ophthalmic emulsion) 0.05% is the first and only therapy for patients with keratoconjunctivitis sicca (Dry Eye Disease) whose tear production is presumed to be supressed d...
ZYMAR™ ophthalmic solution is an anti-infective prescription eye drop that your doctor may instruct you to use if you have an eye infection caused by bacteria. Bacterial conjunctivitis is the e...
... P.M.® lets you sleep on ... in the morning awake with ... ready to take on the ... comfort and protection, this preservative-free ...
Medicine Products: